PCVX Vaxcyte Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: PCVX

Price (delayed)

$84.055

Market cap

$9.14B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.28

Enterprise value

$8.56B

Vaxcyte is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious ...

Highlights
PCVX's quick ratio has surged by 130% since the previous quarter and by 10% year-on-year
Vaxcyte's equity has surged by 110% YoY and by 60% QoQ
The debt has surged by 65% year-on-year but it has declined by 6% since the previous quarter
The net income has plunged by 78% YoY and by 9% from the previous quarter
The EPS has decreased by 24% YoY and by 3.4% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: https://vaxcyte.com/
Peers: OMGA ONCT

Key stats

What are the main financial stats of PCVX
Market
Shares outstanding
108.8M
Market cap
$9.14B
Enterprise value
$8.56B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.59
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$436.82M
EBITDA
-$425.9M
Free cash flow
-$482.56M
Per share
EPS
-$4.28
Free cash flow per share
-$4.32
Book value per share
$18.3
Revenue per share
$0
TBVPS
$18.72
Balance sheet
Total assets
$2.09B
Total liabilities
$107.32M
Debt
$27.42M
Equity
$1.98B
Working capital
$1.43B
Liquidity
Debt to equity
0.01
Current ratio
17.42
Quick ratio
17.07
Net debt/EBITDA
1.37
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-26.9%
Return on equity
-28.8%
Return on invested capital
-42.4%
Return on capital employed
-21.8%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PCVX stock price

How has the Vaxcyte stock price performed over time
Intraday
0.48%
1 week
2.97%
1 month
12%
1 year
78.54%
YTD
33.85%
QTD
11.32%

Financial performance

How have Vaxcyte's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$511.32M
Net income
-$436.82M
Gross margin
N/A
Net margin
N/A
Vaxcyte's operating income has shrunk by 94% YoY and by 9% QoQ
The net income has plunged by 78% YoY and by 9% from the previous quarter

Growth

What is Vaxcyte's growth rate over time

Valuation

What is Vaxcyte stock price valuation
P/E
N/A
P/B
4.59
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has decreased by 24% YoY and by 3.4% from the previous quarter
Vaxcyte's equity has surged by 110% YoY and by 60% QoQ
The P/B is 20% higher than the last 4 quarters average of 3.8 and 14% higher than the 5-year quarterly average of 4.0

Efficiency

How efficient is Vaxcyte business performance
PCVX's ROIC has soared by 56% year-on-year and by 13% since the previous quarter
Vaxcyte's return on equity has increased by 23% YoY and by 10% QoQ
PCVX's ROA is up by 22% YoY and by 9% QoQ

Dividends

What is PCVX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PCVX.

Financial health

How did Vaxcyte financials performed over time
Vaxcyte's current ratio has surged by 131% QoQ and by 9% YoY
PCVX's quick ratio has surged by 130% since the previous quarter and by 10% year-on-year
The debt is 99% smaller than the equity
Vaxcyte's equity has surged by 110% YoY and by 60% QoQ
The debt has surged by 65% year-on-year but it has declined by 6% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.